Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now later-stage tilt small index

Episodic Migraine: later-stage trial registry

7 of 14 indexed Episodic Migraine trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 7 currently recruiting · #1,230 of 28,707 conditions by registered trial count

Episodic Migraine: 14 US clinical trials tracked, 7 recruiting.

Episodic Migraine is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Click Therapeutics, running 2 of these trials.

Enrollment posture brief

Registry condition episodic-migraine

OPEN 7 | RECR 50% | LATE 9 | EARLY 2 | RANK #1230 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Episodic Migraine (this)50%Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly28.6%Abscess7.1%
Open-enrollment share among volume-matched conditions near Episodic Migraine

Episodic Migraine lists 7 open slots (50% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Episodic Migraine on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Episodic Migraine is recruiting above its size-band peers.

    7 of 14 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Episodic Migraine trials is spread across many organizations.

    Click Therapeutics accounts for 2 of 14 trials (14.3%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Episodic Migraine enrolment sits around 568 participants.

    Median target enrolment is 568 among the 14 trials that report a genuine target (sentinel values excluded). 3 of those (21.4%) plan for fewer than 100 participants.

  4. Episodic Migraine research is mostly interventional.

    13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 36Phase 43

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 3 990 participants

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Merz Therapeutics

NCT07018700

RECRUITING 700 participants

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Hospital Universitari Vall d'Hebron Research Institute

NCT07159750

RECRUITING Phase 2 641 participants

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Ipsen

NCT06625060

RECRUITING Phase 3 450 participants

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

AbbVie

NCT05711394

RECRUITING Phase 3 315 participants

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

H. Lundbeck A/S

NCT05897320

RECRUITING NA 60 participants

Chiropractic Care for Episodic Migraine

Brigham and Women's Hospital

NCT06229834

RECRUITING Phase 2 60 participants

Efficacy of Nerve Blocks for Episodic Migraine

Mayo Clinic

NCT05734625

ACTIVE NOT RECRUITING Phase 3 751 participants

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Ipsen

NCT06047457

ACTIVE NOT RECRUITING Phase 3 533 participants

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Eli Lilly and Company

NCT03432286

COMPLETED Phase 4 621 participants

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

Amgen

NCT03927144

COMPLETED Phase 4 580 participants

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Eli Lilly and Company

NCT05127486

COMPLETED NA 568 participants

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Click Therapeutics

NCT05853900

COMPLETED Phase 3 110 participants

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Click Therapeutics

NCT06004388

COMPLETED Phase 4 76 participants

The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache

Beth Israel Deaconess Medical Center

NCT00719134

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 6
Phase 4 3

Named interventions

Most-linked intervention names on Episodic Migraine records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Galcanezumab Drug
2 trials
Placebo Other
2 trials
Click Digital Therapeutic Device
1 trials
Oral Prophylactic Drug
1 trials
AMG334 Drug
1 trials
ReMMi-D Digital Therapeutic Device
1 trials
placebo pills Drug
1 trials

US sites by state

Facility locations filed on Episodic Migraine trials. A trial with sites in several states counts in each.

Florida 8 trials
California 7 trials
Connecticut 5 trials
Arizona 5 trials
New York 4 trials
Georgia 4 trials
Alabama 4 trials
Michigan 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Episodic Migraine page

14 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Episodic Migraine condition card totals 14 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.